NCT07861399 Dual Trigger VS HCG Trigger for Final Oocyte Maturation in Normal Responders
| NCT ID | NCT07861399 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Al-Azhar University |
| Condition | ICSI |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-09-01 |
| Primary Completion | 2028-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2026-09-01 with a primary completion date of 2028-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To compare the embryological and reproductive outcomes of dual trigger versus conventional hCG trigger for final oocyte maturation in normal responder patients undergoing ICSI cycles.
Eligibility Criteria
Inclusion Criteria: * Women aged 20-40 years. * Body mass index (BMI) between 18 and 30 kg/m². * Undergoing ICSI treatment using a GnRH antagonist protocol. * Normal ovarian reserve and expected normal ovarian response. * AMH between 1.2 - 3.5 ng/ml * AFC 7-15 follicle. * First or second ICSI cycle. Exclusion Criteria: * Poor ovarian response (Bologna/POSEIDON criteria) * High ovarian response with a risk of ovarian hyperstimulation syndrome (OHSS) AMH \> 3.5 ng/ml or AFC \> 15 follicle. * Polycystic ovary syndrome (PCOS). * Serum E2 level \> 3500 pg/ml at day of triggering. * Endocrine disorders including diabetes mellitus, thyroid dysfunction, hyperprolactinemia, congenital adrenal hyperplasia, or Cushing syndrome. * Congenital uterine abnormalities. * Severe systemic diseases affecting fertility outcomes.
Contact & Investigator
Ehab HM Hasanin, Professor
STUDY DIRECTOR
Obstetrics and Gynecology Department, Al-Azhar University.
Frequently Asked Questions
Who can join the NCT07861399 clinical trial?
This trial is open to female participants only, aged 20 Years or older, up to 40 Years, studying ICSI. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07861399 currently recruiting?
Yes, NCT07861399 is actively recruiting participants. Contact the research team at agebreel@hotmail.com for enrollment information.
Where is the NCT07861399 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT07861399 clinical trial?
NCT07861399 is sponsored by Al-Azhar University. The principal investigator is Ehab HM Hasanin, Professor at Obstetrics and Gynecology Department, Al-Azhar University.. The trial plans to enroll 100 participants.